Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment

Nephrology

Volumn 13, Issue 3, 2008, Pages 198-203

  Chiang, Wen Chih ^a   Lin, Shuei Liong ^a   Chen, Yung Ming ^a   Wu, Kwan Dun ^a   Tsai, Tun Jun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic kidney disease; Cytokine; Glomerular filtration rate; Kallikrein

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; KALLIKREIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEINURIA; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION MEDIATORS; KALLIKREINS; LOSARTAN; MALE; MIDDLE AGED; NEPHRITIS; PROTEINURIA; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40349116013     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00933.x     Document Type: Article

References (24)

1. Chiang WC, Chien CT, Lin WW et al. Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic. Biol. Med. 2006 41 : 1304 14.
2. Schanstra JP, Neau E, Drogoz P et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J. Clin. Invest 2002 110 : 371 9.
3. Xia CF, Bledsoe G, Chao L, Chao J. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am. J. Physiol. Renal Physiol. 2005 289 : F622 31.
4. Bergmann S, Zheng D, Barredo J, Abboud MR, Jaffa AA. Renal kallikrein: A risk marker for nephropathy in children with sickle cell disease. J. Pediatr. Hematol. Oncol. 2006 28 : 147 53.
5. Brouhard BH, Cunningham RJ, Petrusick TW, Berger M, Travis LB. Urinary kallikrein excretion in idiopathic nephrotic syndrome. J. Urol. 1979 121 : 672 4.
6. Perez-Blanco FJ, Manzanares-Olivares L, Dominguez-Vicent JR, Moreno-Terribas G, Rodriguez-Cuartero A. Urinary kallikrein excretion in early diabetic nephropathy. Clin. Nephrol. 1997 47 : 64 5.
7. Manto A, Cotroneo P, Porcelli G et al. Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993 36 : 423 7.
8. Kimura K, Onodera K, Oike Y et al. A clinical study on urinary kallikrein in patients with renal diseases. Adv. Exp. Med. Biol. 1979 120 : 549 59.
9. Naicker S, Naidoo S, Ramsaroop R, Moodley D, Bhoola K. Tissue kallikrein and kinins in renal disease. Immunopharmacol. 1999 44 : 183 92.
10. Wu TH, Wu SC, Huang TP, Yu CL, Tsai CY. Increased excretion of tumor necrosis factor alpha and interleukin 1 beta in urine from patients with IgA nephropathy and Schonlein-Henoch purpura. Nephron 1996 74 : 79 88.
11. Saitoh A, Sekizuka K, Hayashi T, Kaneko S, Suzuki Y, Tomino Y. Detection of MCP-1 in patients with diabetic nephropathy. Nephron 1998 80 : 99.
12. Goumenos DS, Tsakas S, El Nahas AM et al. Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol. Dial. Transplant. 2002 17 : 2145 52.
13. Catanzaro OL, Martinez Seeber A, Vila SB. Effect of angiotensin, noradrenaline, vasopressin and aldosterone on urinary kallikrein excretion in the rat. Pharmacol. Res. Commun. 1984 16 : 775 83.
14. Hettinger U, Lukasova M., Lewicka S, Hilgenfeldt U. Regulatory effects of salt diet on renal renin-angiotensin-aldosterone, and kallikrein-kinin systems. Int. Immunopharmacol. 2002 2 : 1975 80.
15. Jaffa AA, Silva RH, Kim B, Mayfield RK. Modulation of renal kallikrein production by dietary protein in streptozotocin-induced diabetic rats. J. Am. Soc. Nephrol. 1996 7 : 721 7.
16. Margolius HS, Horwitz D, Geller RG et al. Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 1974 35 : 812 19.
17. Margolius HS, Horwitz D, Pisano JJ, Keiser HR. Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 1974 35 : 820 25.
18. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc. Res. 2004 61 : 663 70.
19. Stadnicki A, Chao J, Stadnicka I et al. Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats. Am. J. Physiol. 1998 275 : G854 61.
20. Devani M, Vecchi M, Ferrero S et al. Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation. Dig. Liver Dis. 2005 37 : 665 73.
21. O'Riordan TG, Weinstein MD, Abraham WM, Forteza R. Elevated tissue kallikrein activity in airway secretions from patients with tracheobronchitis associated with prolonged mechanical ventilation. Lung 2003 181 : 237 44.
22. Okada H, Watanabe Y, Kikuta T et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J. Am. Soc. Nephrol. 2004 15 : 2404 13.
23. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol. Dial. Transplant 2004 19 : 1106 15.
24. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 2006 69 : 1410 15.